Suchen
Immix Biopharma Inc
IMMXZur Watchlist hinzufügen
10.340USD
+0.510+5.19%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
547.51MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Immix Biopharma Inc Unternehmen
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Immix Biopharma Inc Informationen
BörsenkürzelIMMX
Name des UnternehmensImmix Biopharma Inc
IPO-datumDec 16, 2021
CEORachman (Ilya)
Anzahl der mitarbeiter18
WertpapierartOrdinary Share
GeschäftsjahresendeDec 16
Addresse11400 West Olympic Blvd.
StadtLOS ANGELES
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl90064
Telefon18889581084
Websitehttps://immixbio.com/
BörsenkürzelIMMX
IPO-datumDec 16, 2021
CEORachman (Ilya)
Führungskräfte von Immix Biopharma Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
72.34K
+8.64%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
6.25K
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Ilya Rachman, M.D., Ph.D.
Dr. Ilya Rachman, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
72.34K
+8.64%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
6.25K
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Immix Biopharma Inc?
Die fünf größten Anteilseigner von Immix Biopharma Inc sind: Mr. Jason Hsu, Ph.D.
Wie viele Institutionen halten Anteile an Immix Biopharma Inc (IMMX)?
Mit Stand vom 2026Q1 halten 105 Institutionen Anteile an Immix Biopharma Inc, mit einem Gesamtmarktwert von etwa 24.89M, was 45.75% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 18028804.00 gestiegen.